CN112955131A - 用于预防或治疗钙化防御的方法和组合物 - Google Patents

用于预防或治疗钙化防御的方法和组合物 Download PDF

Info

Publication number
CN112955131A
CN112955131A CN201980052691.0A CN201980052691A CN112955131A CN 112955131 A CN112955131 A CN 112955131A CN 201980052691 A CN201980052691 A CN 201980052691A CN 112955131 A CN112955131 A CN 112955131A
Authority
CN
China
Prior art keywords
subject
mkh2
administered
defense
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980052691.0A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·A·图姆林
保罗·L·达克
约翰·M·鲁迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epson Pharmaceutical Co
Original Assignee
Epson Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epson Pharmaceutical Co filed Critical Epson Pharmaceutical Co
Publication of CN112955131A publication Critical patent/CN112955131A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980052691.0A 2018-06-08 2019-06-07 用于预防或治疗钙化防御的方法和组合物 Pending CN112955131A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
US62/682,794 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (1)

Publication Number Publication Date
CN112955131A true CN112955131A (zh) 2021-06-11

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980052691.0A Pending CN112955131A (zh) 2018-06-08 2019-06-07 用于预防或治疗钙化防御的方法和组合物

Country Status (11)

Country Link
US (7) US10736858B2 (https=)
EP (1) EP3801478A4 (https=)
JP (1) JP2021527129A (https=)
KR (1) KR20210018422A (https=)
CN (1) CN112955131A (https=)
AU (1) AU2019282421B2 (https=)
CA (1) CA3102979A1 (https=)
IL (1) IL279246B2 (https=)
MX (2) MX2020013301A (https=)
SG (1) SG11202012055PA (https=)
WO (1) WO2019237054A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
EP3890831A4 (en) * 2019-01-04 2022-09-21 Kaydence Pharma AS COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006607A2 (en) * 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
DE602006020658D1 (de) 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
WO2007095630A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New ubiquinone analogs and methods of use
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
BR112013009724A2 (pt) 2010-11-01 2016-07-19 Viridis Biopharma Pvt Ltd equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
US10159787B2 (en) 2012-06-18 2018-12-25 Fresenius Kabi Deutschland Gmbh Port cannula system for puncturing port catheters
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP2868658B1 (en) 2013-11-01 2018-05-02 Dilip Mehta Method of preparation of stereospecific quinone derivatives
BR112017019750A2 (en) 2015-03-20 2018-05-29 Gnosis S.P.A. process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol
CN206387961U (zh) 2016-12-30 2017-08-08 孙淑芬 头戴显示设备
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
EP3774707A1 (en) 2018-04-06 2021-02-17 Instytut Farmaceutyczny Process of vitamin k 2 derivatives preparation
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006607A2 (en) * 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DANIEL CHRISTIADI等: "Calciphylaxis in a dialysis patient successfully treated with high-dose vitamin K supplementation", 《CLIN KIDNEY J》 *
SCHEIBER D等: "High-Dose Menaquinone-7 supplementation reduces cardiovascular calcification in a murine model of Extraosseous Calcification", 《NUTRIENTS》 *

Also Published As

Publication number Publication date
US20240041794A1 (en) 2024-02-08
US20200306207A1 (en) 2020-10-01
EP3801478A1 (en) 2021-04-14
IL279246B1 (en) 2023-04-01
EP3801478A4 (en) 2022-02-23
US20210378987A1 (en) 2021-12-09
KR20210018422A (ko) 2021-02-17
MX2024010211A (es) 2024-09-02
US20200360301A1 (en) 2020-11-19
IL279246B2 (en) 2023-08-01
IL279246A (en) 2021-01-31
US20200306208A1 (en) 2020-10-01
US12433854B2 (en) 2025-10-07
JP2021527129A (ja) 2021-10-11
MX2020013301A (es) 2021-05-12
AU2019282421B2 (en) 2025-01-09
US11065212B2 (en) 2021-07-20
SG11202012055PA (en) 2021-01-28
US11793773B2 (en) 2023-10-24
US10940123B2 (en) 2021-03-09
AU2019282421A1 (en) 2021-01-07
WO2019237054A1 (en) 2019-12-12
US20200306206A1 (en) 2020-10-01
US10925838B2 (en) 2021-02-23
US20190374483A1 (en) 2019-12-12
US10736858B2 (en) 2020-08-11
US10987320B2 (en) 2021-04-27
CA3102979A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
JP7847880B2 (ja) 組織石灰化を予防または治療するための方法および組成物
US12433854B2 (en) Methods and compositions for preventing or treating calciphylaxis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination